Wormrosales8777

We identified an 11-lncRNA expression signature with high stability and feasibility, which can predict the survival of patients with EC. These findings provide new potential biomarkers to improve the accuracy of prognosis prediction of EC.

The Salford Lung Study (SLS) in chronic obstructive pulmonary disease (COPD) was a randomised controlled trial evaluating the effectiveness and safety of initiating fluticasone furoate/vilanterol (FF/VI) 100/25 µg

continuing usual care (UC) in patients with COPD and a history of exacerbations. Here, we investigate the impact of initiating FF/VI on healthcare resource utilisation (HRU) in SLS COPD.

HRU and interventions were determined from patients' electronic health records. Annual rates of on-treatment all-cause and COPD-related secondary care contacts (SCCs) and primary care contacts (PCCs) for FF/VI

UC were analysed using a general linear model. Costs were derived from national data sources.

Least-squares (LS) mean annual rates of all-cause (9.81

9.36) and COPD-related (1.57

1.48) SCCs were similar for FF/VI and UC, as were rates of all-cause hospitalisations (0.87

0.82). Mean duration of hospital stay/patient was 4.5 and 4.2 days, respectively. COPD-related SCC mean total cost/patient was £484 FF/VI and £475 UC. LS mean annual rates of all-cause PCCs were significantly higher for FF/VI (21.20

18.88 UC;

 < 0.001). LS mean annual rates of COPD-related PCCs were similar for FF/VI and UC (2.42

2.46). All-cause PCC mean total cost/patient was £900 FF/VI

£811 UC, but COPD-related PCC costs were similar (£116

£114). Direct COPD-related total medical costs/patient were significantly lower for FF/VI (LS geometric mean £806

£963 UC;

 < 0.001).

In patients with COPD and exacerbation history, FF/VI may represent a less costly alternative to current therapies.GlaxoSmithKline plc. selleck products study HZC115151; ClinicalTrials.gov NCT01551758.



In patients with COPD and exacerbation history, FF/VI may represent a less costly alternative to current therapies.GlaxoSmithKline plc. study HZC115151; ClinicalTrials.gov NCT01551758.The reviews of this paper are available via the supplemental material section.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease characterized by worsening dyspnea and lung function and has a median survival of 2-3 years. Forced vital capacity (FVC) is the primary endpoint used most commonly in IPF clinical trials as it is the best surrogate for mortality. This study assessed quantitative scores from high-resolution computed tomography (HRCT) developed by machine learning as a secondary efficacy endpoint in a 26-week phase II study of BMS-986020 - an LPA

receptor antagonist - in patients with IPF.

HRCT scans from 96% (137/142) of randomized subjects were utilized. Quantitative lung fibrosis (QLF) scores were calculated from the HRCT images. QLF improvement was defined as ⩾2% reduction in QLF score from baseline to week 26.

In the placebo arm, 5% of patients demonstrated an improvement in QLF score at week 26 compared with 15% and 27% of patients in the BMS-986020 600 mg once daily (QD) and twice daily (BID) arms, respectively [

placebo

 = 0.08 (600 mg QD);

 = 0.0098 (600 mg BID)]. Significant correlations were found between changes in QLF and changes in percent predicted FVC, diffusing capacity for carbon monoxide (DLCO), and shortness of breath at week 26 (

 = -0.41,

 = -0.22, and

 = 0.27, respectively; all

 < 0.01).

This study demonstrated the utility of quantitative HRCT as an efficacy endpoint for IPF in a double-blind, placebo-controlled clinical trial setting.



This study demonstrated the utility of quantitative HRCT as an efficacy endpoint for IPF in a double-blind, placebo-controlled clinical trial setting.The reviews of this paper are available via the supplemental material section.Although significant associations between diurnal preference and restrained eating behaviors were previously reported, such reports are scarce and, in some respects, inconclusive. In this cross-sectional survey of 567 female university students aged between 17 and 23 years, we tried to clarify and extend the previous findings on chronobiological correlates of these behaviors. We administered the three-Factor-Eating-Questionnaire Revised and three questionnaires designed to assess trait-, ability-, and state-like differences in the domain of chronobiology, the Morningness-Eveningness Questionnaire (MEQ), the Sleep-Wake Pattern Assessment Questionnaire, and the Munich ChronoType Questionnaire, respectively. Statistical analyses included factor, correlation, and regression analyses. We found that any of three aspects of unhealthy eating behaviors (i.e., lack of cognitive eating restraint, uncontrolled eating, and emotional eating) was linked to one or more dimensions of individual chronobiological differences. We explained the previously reported inconclusive results by the differential relationship of two subconstructs of diurnal preferences to eating behaviors. For instance, such relationship was found for two (morning and evening) subscales of the MEQ. Cognitive eating restraint and uncontrolled eating were related to the morning subscale, while emotional eating was related to the evening subscale. These associations were supported by the associations revealed for morning vs. evening components of earliness-lateness assessed with two other questionnaires, (e.g., morning lateness and sleep offset vs. evening lateness and sleep onset, respectively). We conclude that unhealthy eating behaviors seem to be linked to unhealthy sleep-wake habits and behaviors and to inabilities to wake or sleep on demand at certain times of the day.Bipolar disorder (BD) is a chronic and burdensome psychiatric disease, characterized by variations in mood and energy. The literature has consistently demonstrated an association between BD and childhood maltreatment (CM), and genetic variants of circadian genes have been associated with an increased vulnerability to develop BD. In this context, environmental factors such as CM may also contribute to the susceptibility to BD through alterations in the functioning of the biological clock linked to modifications of expression of circadian genes. In this study, we explored the associations between childhood maltreatment, sleep quality, and the level of expression of a comprehensive set of circadian genes in lymphoblastoid cell lines from patients with BD. The sample consisted of 52 Caucasian euthymic patients with a diagnosis of BD type 1 or type 2. The exposure to CM was assessed with the Childhood Trauma Questionnaire (CTQ), and the sleep quality was assessed using the Pittsburgh Sleep Quality Index. We measured the expression of 18 circadian genes using quantitative RT-PCR ARNTL2, BHLHE40, BHLHE41, CLOCK, CRY1, CRY2, CSNK1D, CSNK1E, DBP, GSK3B, NPAS2, NR1D1, PER1, PER2, PER3, PPARGC1A, RORA, and RORB.